Vulvar and vaginal atrophy in four European countries: Evidence from the European REVIVE Survey

Climacteric

Volumn 19, Issue 2, 2016, Pages 188-197

  Nappi, R E ^a   Palacios, S ^b   Panay, N ^c   Particco, M ^d   Krychman, M L ^e  

^a UNIVERSITY OF PAVIA   (Italy)

^b Institute Palacios   (Spain)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d SHIONOGI AND CO LTD   (Japan)

^e Southern California Center for Sexual Health and Survivorship Medicine   (United States)

Author keywords

dyspareunia; Europe; postmenopausal women; REVIVE Survey; sexual relationships; treatment; vaginal dryness; Vulvar and vaginal atrophy

Indexed keywords

ESTROGEN; HERBACEOUS AGENT; LUBRICATING AGENT; NON PRESCRIPTION DRUG;

ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; BREAST CANCER; CHRONIC DISEASE; CLIMACTERIUM; COHABITATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOCTOR PATIENT RELATION; DRUG COST; DRUG SAFETY; DYSPAREUNIA; ESTROGEN THERAPY; FEMALE; FRUSTRATION; HEALTH SURVEY; HUMAN; INTIMACY; KNOWLEDGE; LIBIDO; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT PREFERENCE; PATIENT SATISFACTION; PATIENT WORRY; POPULATION DISTRIBUTION; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEXUAL BEHAVIOR; SEXUAL HEALTH; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; VAGINA ATROPHY; VAGINA DISCHARGE; VAGINA DISEASE; VAGINA PAIN; VAGINAL DRYNESS; VAGINAL IRRITATION; VAGINAL LUBRICATION; VAGINAL TENDERNESS; WOMEN'S HEALTH; ATROPHY; EUROPE; PATHOLOGY; QUALITY OF LIFE; VAGINA; VAGINAL DISEASES; VULVA;

AGED; ATROPHY; DYSPAREUNIA; EUROPE; FEMALE; HEALTH SURVEYS; HUMANS; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; SEXUAL BEHAVIOR; VAGINA; VAGINAL DISEASES; VULVA;

EID: 84959376807     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2015.1107039     Document Type: Article

References (33)

1. Lachowsky M, Nappi RE. The effects of oestrogen on urogenital health. Maturitas 2009; 63: 149-51
2. Bruce D, Rymer J. Symptoms of the menopause. Best Pract Res Clin Obstet Gynaecol 2009; 23: 25-32
3. MacBride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010; 85: 87-94
4. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009; 6: 2133-42
5. Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009; 63: 138-41
6. Palacios S. Managing urogenital atrophy. Maturitas 2009; 63: 315-18
7. 2011 EU Census [Internet]. Eurostat, the statistical office of the European Union; 2012. Available from: http://ec.europa.eu/eurostat/web/population-and-housing-census/census-data/2011-census
8. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA)-results from an international survey. Climacteric 2012; 15: 36-44
9. Parish SJ, Nappi RE, Krychman ML., et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health 2013; 5: 437-47
10. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014; 17: 3-9
11. Kingsberg SA, Krychman ML. Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med 2013; 10: 1567-74
12. REVEAL: REvealing Vaginal Effects At mid-Life. Surveys of postmenopausal women and health care professionals who treat postmenopausal women. Madison, NJ: Wyeth, 2009
13. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007; 14: 355-69
14. Tan O, Bradshaw K, Carr BR. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. Menopause 2012; 19: 109-17
15. Shulman LP, Portman DJ, Lee WC., et al. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice. J Womens Health 2008; 17: 569-78
16. Nappi RE, Nijland EA. Womens perception of sexuality around the menopause: outcomes of a European telephone survey. Eur J Obstet Gynecol Reprod Biol 2008; 137: 10-16
17. Pfizer Pharmaceuticals, Inc. Healthy women survey [Internet]. 2012 [cited 2012 Aug 11]. Available from: www.personalmenopauseanswers.com/healthy-women-survey.aspx
18. News release from Novo Nordisk. Data reveal the negative emotional and physical impact that a silent symptom of menopause has on U.S. women and their partners. October 5, 2012
19. Nappi RE, Mattsson L-Å, Lachowsky M, Maamari R, Giraldi A. The CLOSER survey: Impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe. Maturitas 2013; 75: 373-9
20. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Womens VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013; 10: 1790-9
21. Sutton KS, Boyer SC, Goldfinger C, Ezer P, Pukall CF. To lube or not to lube: experiences and perceptions of lubricant use in women with and without dyspareunia. J Sex Med 2012; 9: 240-50
22. Portman DJ, Gass ML,; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Womens Sexual Health and the North American Menopause Society. Climacteric 2014; 17: 557-63
23. Nappi RE, Kokot-Kierepa M. Womens voices in the menopause: Results from an international survey on vaginal atrophy. Maturitas 2010; 67: 233-8
24. Cumming GP, Currie HD, Moncur R, Lee AJ. Web-based survey on the effect of menopause on womens libido in a computer-literate population. Menopause Int 2009; 15: 8-12
25. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000; 96: 351-8
26. Avis NE, Zhao X, Johannes CB, Ory M, Brockwell S, Greendale GA. Correlates of sexual function among multi-ethnic middle-aged women: results from the Study of Womens Health Across the Nation (SWAN). Menopause 2005; 12: 385-98
27. Simon J, Komi J. Vulvovaginal atrophy (VVA) negatively impacts sexual function, psychosocial well-being, and partner relationships. In Proceedings of the North American Menopause Society (NAMS). Dallas, TX, USA; 2007
28. Sobecki JN, Curlin FA, Rasinski KA, Lindau ST. What we dont talk about when we dont talk about sex: results of a national survey of U.S. obstetrician/gynecologists. J Sex Med 2012; 9: 1285-94
29. Bachmann GA, Leiblum SR, Grill J. Brief sexual inquiry in gynecologic practice. Obstet Gynecol 1989; 73: 425-7
30. Kingsberg S, Kellogg S, Krychman M. Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy. Int J Womens Health 2010; 1: 105-11
31. Sturdee DW, Pines A, International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011; 14: 302-20
32. Rees M, Pérez-López FR, Ceasu I., et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas 2012; 73: 171-4
33. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17: 242-55